WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018019900) ORAL COMPOSITION OF ANTI-TNF-ALPHA ANTIBODIES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/019900 International Application No.: PCT/EP2017/068918
Publication Date: 01.02.2018 International Filing Date: 26.07.2017
Chapter 2 Demand Filed: 21.03.2018
IPC:
A61K 9/16 (2006.01) ,A61K 9/19 (2006.01) ,A61K 39/395 (2006.01)
Applicants: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES[FR/FR]; 3 avenue des Tropiques ZA de Courtaboeuf 91940 LES ULIS, FR
Inventors: GAUCHER, Christine; FR
HANDKE, Nadège; FR
JAUME, Cécile; FR
Agent: PONTET ALLANO & ASSOCIES; Parc Les Algorithmes Bâtiment PLATON CS 70003 SAINT-AUBIN 91192 GIF SUR YVETTE Cedex, FR
Priority Data:
165744229.07.2016FR
Title (EN) ORAL COMPOSITION OF ANTI-TNF-ALPHA ANTIBODIES
(FR) COMPOSITION ORALE D'ANTICORPS ANTI-TNF ALPHA
Abstract:
(EN) The present application relates to a pharmaceutical composition for oral administration, comprising a monoclonal anti-tumor necrosis factor alpha antibody (TNFα) and at least one or more pharmaceutically acceptable excipients selected from the group comprising: a carboxymethyl-dextran, a chitosan, a cyclodextrin, or a combination of same, as well as the use of said composition in the treatment of inflammatory diseases or autoimmune diseases.
(FR) La présente demande concerne une composition pharmaceutique pour administration orale, comprenant un anticorps monoclonal anti-facteur de nécrose tumorale alpha (TNFα) et au moins un ou plusieurs excipients pharmaceutiquement acceptables choisis dans le groupe comprenant: un carboxyméthyle-dextran, un chitosan, une cyclodextrine ou une combinaison de ceux-ci, ainsi que l'utilisation de cette composition dans le traitement des maladies inflammatoires ou des maladies auto-immunes.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: French (FR)
Filing Language: French (FR)